Antibiotic

Researchers Discover Critical Role of Hydrogen Sulfide in Ability of Bacteria to Survive Antibiotics

Retrieved on: 
Thursday, June 10, 2021
Microbiology, Branches of biology, Medical specialties, Bacteriology, Antibiotic resistance, Bacteria, Persister cells, Biofilm, Antibiotic, Hydrogen sulfide

NEW YORK, June 10, 2021 /PRNewswire/ -- The signaling molecule hydrogen sulfide (H2S) plays a critical role in antibiotic tolerance, the innate ability of bacteria to survive normally lethal levels of antibiotics, a new study finds.

Key Points: 
  • NEW YORK, June 10, 2021 /PRNewswire/ -- The signaling molecule hydrogen sulfide (H2S) plays a critical role in antibiotic tolerance, the innate ability of bacteria to survive normally lethal levels of antibiotics, a new study finds.
  • In one defense mechanism, tolerant bacteria, also called "persisters," stop multiplying (proliferating), reducing their energy use (metabolism) to survive antibiotic treatment, but resuming growth when the treatment ends.
  • Persisters are particularly abundant in biofilms, bacterial colonies that live in tough polymeric matrices which further prevent their eradication.
  • "New approaches are urgently neededto preventthis, and our study suggeststhatsuppressing bacterial H2S would make different antibiotics more potent."

Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus

Retrieved on: 
Thursday, June 10, 2021
Health sciences, Epidemiology, Health, Omadacycline, Clinical trial, Cohort study, Infection, Antibiotic

During the webinar, Paratek will provide a corporate overview and an update on NUZYRA (omadacycline), the companysonce-daily oral and intravenous antibiotic and discuss future development opportunities.

Key Points: 
  • During the webinar, Paratek will provide a corporate overview and an update on NUZYRA (omadacycline), the companysonce-daily oral and intravenous antibiotic and discuss future development opportunities.
  • His Center for Infectious Disease Studies has served as the lead institution and coordinating center for multiple cohort studies and clinical trials.
  • As the public face of the organization, she presents regularly at conferences on a variety of subjects including patient engagement and original patient preference research.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.

Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123 to Treat C. difficile Infections

Retrieved on: 
Monday, June 7, 2021
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Bacteria, Clinical medicine, Clostridioides difficile infection, Diarrhea, Clostridioides difficile, Helicobacter pylori, Antibiotic, CDI

Crestone, Inc. today announced the first patient has been enrolled in a Phase 2 clinical trial of CRS3123 for the treatment of Clostridioides difficile infection (CDI).

Key Points: 
  • Crestone, Inc. today announced the first patient has been enrolled in a Phase 2 clinical trial of CRS3123 for the treatment of Clostridioides difficile infection (CDI).
  • Crestone, Inc. enrolls first patient in Phase 2 clinical trial for novel antibiotic CRS3123 to treat C. difficile infections.
  • Crestone, Inc. Secures NIH Funding for Development Through Phase 1 of Novel Antibiotic Candidate CRS0540, A Novel Inhibitor of DNA Replication in Gram-positive Pathogens.
  • Crestone, Inc. Secures NIH Funding for Preclinical Development of Novel Antibiotic CRS3123 to Treat H. pylori Infections.

We Must Reduce the Misuse of Antibiotics

Retrieved on: 
Tuesday, June 1, 2021
Health sciences, Articles, Pharmaceuticals policy, Veterinary medicine, Health, Antibiotic resistance, Evolutionary biology, Antimicrobial resistance, Antibiotic misuse, Antibiotic, Antibiotic use in livestock

BALTIMORE, Md., June 1, 2021 /PRNewswire/ --Antibiotic resistance is a global health crisis, and it's fueled by theoveruse of antibiotics in livestock.

Key Points: 
  • BALTIMORE, Md., June 1, 2021 /PRNewswire/ --Antibiotic resistance is a global health crisis, and it's fueled by theoveruse of antibiotics in livestock.
  • More than 80% of antibiotics soldin the U.S. go to farm animals.
  • Tostrengthen our food systems, we mustreduce the misuse of antibiotics.
  • WHAT: A virtual panel discussing the misuse of antibiotics.

Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates World First Multiple Mechanisms of Action against E. coli bacteria

Retrieved on: 
Tuesday, June 1, 2021
Medical specialties, Infectious diseases, Medicine, Bacterial diseases, Pathogenic bacteria, Healthcare-associated infections, Antimicrobial resistance, Evolutionary biology, Staphylococcus aureus, Antibiotic, Bloodstream infections, Escherichia coli

The study was performed by independent, world leaders in bacterial Mechanism of Action analysis and antibiotic profiling.

Key Points: 
  • The study was performed by independent, world leaders in bacterial Mechanism of Action analysis and antibiotic profiling.
  • All conditions started with 1x108 CFU/ml E. coli cells which were then treated with R327 for the indicated period of time.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Patented lead candidate RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria including their superbug forms.

Global Hospital Acquired Infections Therapeutic Market (2021 to 2028) - Featuring Pfizer, Bayer and GlaxoSmithKline Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, May 28, 2021
Infectious diseases, Hospitals, Pharmaceutical, Health, Health, Medical specialties, Infectious diseases, Hospital-acquired infection, Infection, Antibiotic, Urinary tract infection, Antimicrobial resistance, Arenicin

The global hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study.

Key Points: 
  • The global hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study.
  • Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections.
  • The majority of players in the market for hospital acquired infections therapeutic are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.
  • The publisher segmented the hospital acquired infections therapeutic market report on the basis of drug class, infection type, and region:

Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

Retrieved on: 
Tuesday, May 25, 2021
Chemical compounds, Drugs, Cyclopropanes, Moxifloxacin, Health care, Antibiotic, Pneumonia, Empiric

Subjects were randomized 2:1 to lefamulin and moxifloxacin and stratified by prior antibiotic exposure, pneumonia severity index (PSI) risk class, and renal impairment.

Key Points: 
  • Subjects were randomized 2:1 to lefamulin and moxifloxacin and stratified by prior antibiotic exposure, pneumonia severity index (PSI) risk class, and renal impairment.
  • These results are similar to those observed in the global Phase 3 LEAP 1 and LEAP 2 clinical trials conducted by Nabriva.
  • We are delighted with the results of this trial, said Dr. Rae Yuan, CEO of Sinovant.
  • These data strongly support the use of lefamulin as an empiric monotherapy for CABP, a disease that affects millions of Chinese patients annually.

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Friday, May 21, 2021
Chemical compounds, Pyridines, Tedizolid, Tetrazoles, Fosfomycin, Antibiotic, Infection, Urinary tract infection

b'DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.\nNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.

Key Points: 
  • b'DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.\nNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA\xc2\xae (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO\xe2\x84\xa2 (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO\xc2\xae (tedizolid phosphate) in the United States and certain of its territories.\n'

European $13.5 Billion Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration - Opportunity Analysis and Industry Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021
Health, Pharmaceutical, Health sciences, Articles, Health, Pharmaceuticals policy, Veterinary medicine, Antibiotic resistance, Evolutionary biology, Antimicrobial resistance, Antibiotic misuse, Antibiotic, Drug resistance, Antibiotic use in livestock

b'The "European Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration: Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com\'s offering.\nThe European antibiotics market was valued at $11,561 million in 2019, and is projected to reach $13,529 million by 2027 at a CAGR of 1.9% from 2020 to 2027.\nThere is an increase in the demand for antibiotics, owing to rise in prevalence of infectious diseases.

Key Points: 
  • b'The "European Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration: Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com\'s offering.\nThe European antibiotics market was valued at $11,561 million in 2019, and is projected to reach $13,529 million by 2027 at a CAGR of 1.9% from 2020 to 2027.\nThere is an increase in the demand for antibiotics, owing to rise in prevalence of infectious diseases.
  • In addition, development of novel approaches for new antibiotics for treating bacterial infections and a large number of clinical trials further drive the market growth.\nHowever, development of antibiotic resistance, driven by misuse of antibiotics and the time taken for the regulatory approval is projected to impede the market growth.\nOn the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.\n'

Basilea awarded CARB-X grant of up to USD 2.7 million to develop novel-class antibiotic

Retrieved on: 
Wednesday, May 19, 2021
Health sciences, Health, Medicine, Pharmaceuticals policy, Veterinary medicine, Evolutionary biology, Immunology, Antimicrobial resistance, Antibiotic, Drug resistance

The funding will support an ongoing Basilea research program to develop an antibiotic from a novel class for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.\nThe program aims to develop selective small-molecule inhibitors of DXR, an enzyme in the bacterial isoprenoid biosynthesis pathway.

Key Points: 
  • The funding will support an ongoing Basilea research program to develop an antibiotic from a novel class for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.\nThe program aims to develop selective small-molecule inhibitors of DXR, an enzyme in the bacterial isoprenoid biosynthesis pathway.
  • Laurenz Kellenberger, Chief Scientific Officer, said: \xe2\x80\x9cThe medical problem of antimicrobial resistance keeps increasing.
  • Therefore, new antibiotics are urgently needed that will be able to address resistance that is growing against current treatment options.
  • We are delighted to be partnering with CARB-X for the development of truly innovative antibiotics directed against this unexploited bacterial target.